Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

- PMLiVE

Running medical meetings

Learning from large-scale events

- PMLiVE

NICE refuses to back Zaltrap as Sanofi exhausts its options

Patient access scheme and appeal fail to overcome cost concerns

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

Selfie campaign boosts cancer funds

Raises more than £8m for cancer charities

- PMLiVE

Gilead taken to task over Sovaldi pricing

US politicians question high cost of new hepatitis C drug

- PMLiVE

Pfizer’s meningitis vaccine ‘a breakthrough’

FDA to speed up review process for bivalent rLP2086

Lilly launches online training to boost patient voice in HTA

New tool aims to help patient advocates 'better influence decisions'

- PMLiVE

Ben Fisher to lead Hive’s med ed agency

He joins Pollen from Ogilvy Healthworld

- PMLiVE

Stargazing in biotech

How to spot the stars of your development portfolio and identify the winning products of the future

- PMLiVE

Celgene gets FDA OK for first oral psoriatic arthritis drug

Otezla wins US approval to treat the auto-immune disease

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

- PMLiVE

Boehringer/Lilly’s empagliflozin among CHMP recommendations

If approved it will be marketed as Jardiance

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links